Fog. 64.5   F New York
AI-Powered News Summarizer
Top Stories

Big global study finds remdesivir doesn't help Covid-19 patients

October 16, 2020. Summarized by summa-bot.

Remdesivir has "little or no effect on mortality" for patients hospitalized with coronavirus and it doesn't seem to help Covid-19 patients recover any faster, either.

(CNN)In a study it described as both conclusive and disappointing, the World Health Organization said the antiviral drug remdesivir has "little or no effect on mortality" for patients hospitalized with coronavirus and it doesn't seem to help patients recover any faster, either.

The WHO study reviewed remdesivir and three other repurposed drugs: hydroxychloroquine, the HIV combination of lopinavir and ritonavir and interferon.

"For each drug in the study, the effect on mortality was disappointingly unpromising," WHO said in a statement.

Several other studies had found that hydroxychloroquine, an anti-malarial drug, was of no benefit to coronavirus patients, as had several studies looking at the HIV drug combination.

Gilead Sciences, the drug's maker, said the findings did not mean the drug, sold under the brand name Veklury, is of no benefit.

"The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of Veklury (remdesivir).

"The benefits of Veklury have been demonstrated in three randomized, controlled clinical trials, including a randomized, double-blind, placebo-controlled clinical trial -- the gold standard for evaluating the efficacy and safety of investigational drugs. "

"Newer antiviral drugs, immunomodulators and anti-SARS COV-2 monoclonal antibodies are now being considered for evaluation via the Solidarity Therapeutics trial," WHO said.

Summarizer is on Google News. Now you can get the latest AI summarized news on your favorite news platform.

Don't like Google News? We have an RSS Feed for you.

Suggestions